Johnson & Johnson (JNJ): Today's Featured Drugs Winner

Johnson & Johnson ( JNJ) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day up 1.4%. By the end of trading, Johnson & Johnson rose 66 cents (1%) to $64.43 on average volume. Throughout the day, 11.1 million shares of Johnson & Johnson exchanged hands as compared to its average daily volume of 10.2 million shares. The stock ranged in a price between $63.84-$64.58 after having opened the day at $63.96 as compared to the previous trading day's close of $63.77. Other companies within the Drugs industry that increased today were: Medgenics ( MDGN), up 23.5%, Amyris ( AMRS), up 19.2%, Accelr8 Technology Corporation ( AXK), up 18.1%, and Biodel ( BIOD), up 15.2%.

Johnson & Johnson engages in the research, development, manufacture, and sale of various products in the health care field worldwide. Johnson & Johnson has a market cap of $173.97 billion and is part of the health care sector. The company has a P/E ratio of 17.8, above the average drugs industry P/E ratio of 17.4 and above the S&P 500 P/E ratio of 17.7. Shares are down 2.8% year to date as of the close of trading on Tuesday. Currently there are 12 analysts that rate Johnson & Johnson a buy, no analysts rate it a sell, and 11 rate it a hold.

TheStreet Ratings rates Johnson & Johnson as a buy. The company's strengths can be seen in multiple areas, such as its growth in earnings per share, expanding profit margins, increase in net income and increase in stock price during the past year. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results.

On the negative front, Idera Pharmaceuticals ( IDRA), down 20.3%, NeurogesX ( NGSX), down 10.8%, Chemocentryx ( CCXI), down 8.5%, and Anthera Pharmaceuticals ( ANTH), down 7.5%, were all losers within the drugs industry with Questcor Pharmaceuticals ( QCOR) being today's drugs industry loser.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).
null

If you liked this article you might like

Roku, Nucana and Other IPOs That Should Be on Your Radar in 2017

Crazy Weak U.S. Dollar Will Make These 10 Companies Huge Winners

Cramer: Goldman's Downgrade Of J&J Is 'Questionable'

Johnson & Johnson Stock Sinks, Goldman Downgrades to 'Sell'

The Best Companies for Women